JANSSEN pharmaceuticals has announced the addition to the Australian Register of Therapeutic Goods of a new biologic therapy for psoriasis, which it says is set to challenge the current dominance of Humira (adalimumab).
Tremfya (guselkumab) is the first biologic approved in Australia that selectively blocks cytokine IL-23, a protein that plays a critical role in the pathogenesis of plaque psoriasis, the company said.
Tremfya is not funded on the PBS, but the company is running a special access scheme.
MEANWHILE in another release, the Pharmaceutical Benefits Scheme (PBS) is now funding Allergan's Ozurdex (dexamethasone 700g) a sustained-release intravitreal implant for patients with non-infectious posterior segment uveitis, along with other specific conditions.
See the PI at allergan.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Apr 18
